Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. - Krishnan M; Bociek RG; Fanale M; Iyer SP; Lechowicz MJ; Bierman PJ; Armitage JO; Lunning M; Kallam A; Vose JM (Annals of hematology, 2022)